Biogen Inc (NASDAQ:BIIB) Shares Bought by Natixis

Share on StockTwits

Natixis raised its position in shares of Biogen Inc (NASDAQ:BIIB) by 7.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 140,745 shares of the biotechnology company’s stock after purchasing an additional 9,687 shares during the quarter. Natixis owned 0.07% of Biogen worth $40,850,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Hugh Johnson Advisors LLC raised its holdings in shares of Biogen by 2.4% during the second quarter. Hugh Johnson Advisors LLC now owns 6,092 shares of the biotechnology company’s stock valued at $1,768,000 after acquiring an additional 145 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its holdings in shares of Biogen by 2.8% during the second quarter. Cambridge Investment Research Advisors Inc. now owns 5,332 shares of the biotechnology company’s stock valued at $1,548,000 after acquiring an additional 147 shares during the last quarter. Greatmark Investment Partners Inc. raised its holdings in shares of Biogen by 4.7% during the second quarter. Greatmark Investment Partners Inc. now owns 3,475 shares of the biotechnology company’s stock valued at $1,009,000 after acquiring an additional 155 shares during the last quarter. Patton Albertson Miller Group LLC raised its holdings in shares of Biogen by 4.0% during the second quarter. Patton Albertson Miller Group LLC now owns 4,453 shares of the biotechnology company’s stock valued at $1,292,000 after acquiring an additional 172 shares during the last quarter. Finally, 6 Meridian raised its holdings in shares of Biogen by 0.9% during the second quarter. 6 Meridian now owns 19,503 shares of the biotechnology company’s stock valued at $5,661,000 after acquiring an additional 176 shares during the last quarter. Hedge funds and other institutional investors own 87.46% of the company’s stock.

Shares of NASDAQ BIIB traded down $1.90 during mid-day trading on Friday, hitting $338.68. The company had a trading volume of 870,789 shares, compared to its average volume of 856,417. Biogen Inc has a 1-year low of $249.17 and a 1-year high of $388.67. The company has a current ratio of 2.36, a quick ratio of 2.06 and a debt-to-equity ratio of 0.48. The stock has a market cap of $68.50 billion, a P/E ratio of 15.53, a PEG ratio of 1.31 and a beta of 0.90.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Tuesday, July 24th. The biotechnology company reported $5.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $5.22 by $0.58. Biogen had a return on equity of 38.17% and a net margin of 23.06%. The company had revenue of $3.36 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the firm earned $5.04 earnings per share. Biogen’s quarterly revenue was up 9.1% on a year-over-year basis. equities analysts forecast that Biogen Inc will post 25.34 EPS for the current fiscal year.

BIIB has been the subject of a number of research analyst reports. Citigroup raised Biogen from a “neutral” rating to a “buy” rating and set a $371.00 target price for the company in a report on Friday, July 6th. Cowen restated a “buy” rating and issued a $408.00 price target on shares of Biogen in a research report on Tuesday, July 24th. SunTrust Banks upped their price target on Biogen from $321.00 to $392.00 and gave the company a “buy” rating in a research report on Wednesday, July 25th. Cantor Fitzgerald set a $293.00 price target on Biogen and gave the company a “hold” rating in a research report on Wednesday, July 25th. Finally, Nomura restated a “buy” rating and issued a $420.00 price target on shares of Biogen in a research report on Friday, July 6th. Nine research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $375.52.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy.

Recommended Story: Index Funds

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.